ProCE Banner Activity

My Thoughts on Optimizing Induction Therapy for MCL

Clinical Thought
Induction therapy in mantle cell lymphoma is rapidly evolving. How do you treat your patients with MCL?

Released: April 30, 2018

Expiration: April 29, 2019

No longer available for credit.

Share

Faculty

Julie M. Vose

Julie M. Vose, MD

Neumann M. and Mildred E. Harris Professor
Chief
, Section of Hematology/Oncology
Professor of Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca Pharmaceuticals

Pharmacyclics Inc

Faculty Disclosure

Primary Author

Julie M. Vose, MD

Neumann M. and Mildred E. Harris Professor
Chief
, Section of Hematology/Oncology
Professor of Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Julie M. Vose, MD, MBA, has disclosed that she has received consulting fees from AbbVie, Epizyme, Karyopharm, Legend Pharmaceuticals, Novartis, Roche, Sandoz, and Vanlam Group and funds for research support from Acerta Pharma, Bristol-Myers Squibb, Celgene, Incyte Corporation, Kite Pharmaceuticals, Merck Sharpe & Dohme, Novartis, and Seattle Genetics.